Key Stats for Soleno Therapeutics Stock
- Pre-market price change for Soleno Therapeutics stock: 33%
- $INTC Stock Price as of Apr. 2: $52
- 52-Week High: $90
- $INTC Stock Price Target: $105
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Soleno Therapeutics (SLNO) stock is surging after the Financial Times reported Sunday that Neurocrine Biosciences is in advanced talks to acquire the company.
- The deal could value Soleno in the low-to-mid $50s per share — implying a total value of more than $2.5 billion.
- According to the report, talks are moving fast, and a deal could be announced as soon as Monday.
Soleno makes VYKAT XR, the first FDA-approved drug to treat hyperphagia — a severe and constant hunger that affects people with Prader-Willi syndrome.
There are no other approved treatments for this condition, which makes VYKAT XR a uniquely valuable asset.
The drug has only been on the market since March 2025, but the launch has been strong. In less than nine months after commercial availability, Soleno generated $190 million in revenue and became profitable for the full year, with net income of $20.9 million.
Q4 alone brought in $91.7 million in revenue, up nearly 40% from Q3.
HC Wainwright analysts estimate VYKAT XR could generate up to $2.3 billion annually at peak sales.
That kind of earning potential makes this a compelling acquisition for Neurocrine, which would be making its first major deal.
See analysts’ growth forecasts and price targets for Soleno Therapeutics stock (It’s free) >>>
What the Market Is Telling Us About Soleno Therapeutics Stock
Soleno Therapeutics stock has been viewed as a takeover target for months.
The drug’s rare disease designation, strong launch trajectory, and lack of competition made it an obvious target for a larger pharma company looking to add a proven revenue stream.
Soleno Therapeutics stock was already up nearly 25% over the past week as biotech M&A activity broadly picked up.
For context, Soleno ended 2025 with over $500 million in cash, 859 active patients on VYKAT XR, and a clear path to expand into Europe and into new indications such as glycogen storage disease.
Neurocrine would be acquiring a business that is already profitable, growing fast, and has a significant runway ahead.
Soleno Therapeutics stock is now trading near the reported deal range, suggesting the market views the deal as likely to close.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Soleno Therapeutics Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
